The National Cancer Institute approved the following clinical research studies last month.
On Nov. 5, as the American people expressed their will, electing Donald Trump to a second term, I started to wonder what my friends in oncology were thinking.
NCI Trials for June 2024
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
As the Trump administration stands poised to redraft the nation’s public health priorities, the American Cancer Society, one of the most prominent advocates for cancer patients, finds itself in an interregnum, following an abrupt departure of its Chief Executive Officer Karen E. Knudsen.
In this week’s issue of JAMA Oncology, there is an important paper that provides information concerning the long-term adverse effects and complications of prostate cancer screening and treatment. xxx:more
When Judith O. Hopkins started medical school in 1974, she had to sign a contract promising to not get pregnant. This was not the most egregious form of sexism she would face in her career. Seeking a residency in emergency medicine in 1977, she was told point blank that she would not be considered. “I...
The National Academy of Medicine announced the election of 90 regular members and 10 international members during its annual meeting.
As oncology contemplates the potential impact of a second Donald Trump term on cancer care and research, The Cancer Letter has compiled a list of guest editorials, news analyses, and data-driven reports that this magazine published during his first term.
